A targeted treatment for emphysema?

August 04, 2020

Emphysema is a progressive, debilitating lung disease in which the lung's breathing sacs, or alveoli, enlarge, get thinner, and eventually are destroyed as the cells die off. It can be fatal, and there is currently no cure. New research at Boston Children's Hospital, using lung cells and mouse models of emphysema, offers hope in the form of a small, engineered peptide molecule called PR1P. Findings were published July 14 in the .

The peptide was developed by

"VEGF is found at high levels in the normal lung -- more than 500 times the levels seen in blood plasma," says Adini. "VEGF levels tend to become dramatically disrupted during lung disease, but return to normal during recovery. It is not clear whether VEGF dysregulation is the root cause of lung disease, or the result of the lung pathology. In emphysema, VEGF activity is low."

Maintaining VEGF levels in the lung

The scientists' first thought was to try to give VEGF directly as a therapy, but VEGF has a very short half-life and can potentially produce serious side effects, including low blood pressure, in animal models.

"So we asked, could there be an alternative way to upregulate VEGF signaling to make it more potent, rather than directly boost VEGF concentrations in the lung?" says Adini.

Serendipitously, through previous research on melanoma, Adini discovered a protein called prominin-1 bound directly to VEGF. Using molecular biology and genetic engineering approaches, he and his colleagues fashioned PR1P, a small peptide comprised of the same 12 amino acids that prominin-1 uses to bind to VEGF.

Protecting the lungs in emphysema models

When the team tested PR1P in lung cells and mouse models of emphysema, they found that it protected VEGF from being degraded. In fact, mice that inhaled PR1P had significantly increased VEGF levels in their lungs as early as 30 minutes after treatment. VEGF levels remained twice as high as in control animals 24 hours later.

Importantly, the researchers further found that PR1P reduced apoptosis (programmed cell death, a key feature in emphysema) in both cell cultures and in live mice. Finally, they showed that PR1P reduced lung damage in mice with toxin-induced emphysema that were followed for 4 and 21 days. Although the study was not designed to assess toxicity, they did not observe any adverse effects.

In addition to emphysema, PR1P may have therapeutic potential for acute respiratory distress syndrome (ARDS), a common and devastating disease which also has no cure and is also characterized by abnormalities in VEGF signaling. Adini and Matthews have funding from the Boston Biomedical Innovation Center (B-BIC) to support their ongoing work to develop PR1P as a therapeutic for both emphysema and ARDS.

"We are now also seeing dramatic lung-preserving and anti-inflammatory effects of inhaled PR1P in mice exposed to multiple diverse toxins that induce lung injury in ARDS models," says Adini.
-end-

About Boston Children's Hospital


Boston Children's Hospital

Related Emphysema Articles from Brightsurf:

Lung-specific risk factors may increase hip fracture risk in individuals who smoke
Smoking has been linked to a higher risk of bone fractures.

A targeted treatment for emphysema?
Emphysema is a progressive, debilitating lung disease in which the lung's breathing sacs, or alveoli, enlarge, get thinner, and eventually are destroyed as the cells die off.

E-cigs can trigger same lung changes seen in smokers, emphysema
In a study published in the American Journal of Respiratory and Critical Care Medicine, the UNC scientists found that the lungs of vapers -- like the lungs of smokers -- have elevated levels of protease enzymes, a condition known to cause emphysema in smokers.

Exposure to outdoor air pollutants, change in emphysema, lung function
Whether exposure to outdoor air pollutants is associated with emphysema progression and change in lung function was the focus of this observational study.

Study finds link between long-term exposure to air pollution and emphysema
Long-term exposure to air pollution was linked to increases in emphysema between 2000 and 2018, according to a new study funded by the National Institute of Environmental Health Sciences (NIEHS) and the National Heart, Lung, and Blood Institute (NHLBI), both part of the National Institutes of Health.

Pollutant linked to climate change accelerates lung disease
A new multicenter study at Columbia University links long-term exposure to air pollution, especially ozone, to development of emphysema, accelerating lung disease progression as much as a pack a day of cigarettes.

Piedmont Atlanta first in Georgia to offer new minimally invasive treatment for emphysema
Piedmont Atlanta Hospital is the first in the state of Georgia to offer a new minimally invasive treatment for emphysema, a severe form of Chronic Obstructive Pulmonary Disease (COPD).

MedStar Franklin Square to offer new treatment option for qualified emphysema patients
MedStar Franklin Square is the first medical facility in the state to offer endoscopic lung volume reduction (ELVR), using a new FDA-approved lung valve that is positioned in damaged lung airways without surgery, and allows patients with severe emphysema to breathe easier.

Protein may slow progression of emphysema, Rutgers study finds
A protein generated as part of our body's immune response to intestinal worms could slow the progression of emphysema, according to a Rutgers study.

Temple Lung Center director reports ongoing positive results for emphysema treatment study
Dr. Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, announced the 12-month results of the EMPROVE multicenter, randomized and controlled study for the Spiration® Valve System (SVS), a minimally invasive treatment for severe emphysema, at the European Respiratory Society International Congress (ERS) in Paris, France, on Sept.

Read More: Emphysema News and Emphysema Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.